Literature DB >> 20739514

Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model.

Dennis A Bente1, Judie B Alimonti, Wun-Ju Shieh, Gaëlle Camus, Ute Ströher, Sherif Zaki, Steven M Jones.   

Abstract

Tick-borne Crimean-Congo hemorrhagic fever virus (CCHFV) causes a severe hemorrhagic syndrome in humans but not in its vertebrate animal hosts. The pathogenesis of the disease is largely not understood due to the lack of an animal model. Laboratory animals typically show no overt signs of disease. Here, we describe a new small-animal model to study CCHFV pathogenesis that manifests clinical disease, similar to that seen in humans, without adaptation of the virus to the host. Our studies revealed that mice deficient in the STAT-1 signaling molecule were highly susceptible to infection, succumbing within 3 to 5 days. After CCHFV challenge, mice exhibited fever, leukopenia, thrombocytopenia, and highly elevated liver enzymes. Rapid viremic dissemination and extensive replication in visceral organs, mainly in liver and spleen, were associated with prominent histopathologic changes in these organs. Dramatically elevated proinflammatory cytokine levels were detected in the blood of the animals, suggestive of a cytokine storm. Immunologic analysis revealed delayed immune cell activation and intensive lymphocyte depletion. Furthermore, this study also demonstrated that ribavirin, a suggested treatment in human cases, protects mice from lethal CCHFV challenge. In conclusion, our data demonstrate that the interferon response is crucial in controlling CCHFV replication in this model, and this is the first study that offers an in-depth in vivo analysis of CCHFV pathophysiology. This new mouse model exhibits key features of fatal human CCHF, proves useful for the testing of therapeutic strategies, and can be used to study virus attenuation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20739514      PMCID: PMC2953203          DOI: 10.1128/JVI.01383-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

Review 1.  Mechanisms of action of ribavirin in antiviral therapies.

Authors:  R C Tam; J Y Lau; Z Hong
Journal:  Antivir Chem Chemother       Date:  2001-09

Review 2.  Treatment of Crimean-Congo hemorrhagic fever.

Authors:  Onder Ergonul
Journal:  Antiviral Res       Date:  2007-12-03       Impact factor: 5.970

3.  Analysis of lymphocyte subgroups in Crimean-Congo hemorrhagic fever.

Authors:  Esragül Akinci; Mesude Yilmaz; Hürrem Bodur; Pinar Ongürü; Fatma Nurhayat Bayazit; Ayşe Erbay; Gülsüm Ozet
Journal:  Int J Infect Dis       Date:  2008-12-27       Impact factor: 3.623

4.  DEBATE (see Elaldi N et al, Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. Journal of Infection 2009; 58: 238-244): Biases and misinterpretation in the assessment of the efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever.

Authors:  Onder Ergonul
Journal:  J Infect       Date:  2009-08-21       Impact factor: 6.072

5.  Congo virus: a hitherto undescribed virus occurring in Africa. II. Identification studies.

Authors:  J P Woodall; M C Williams; D I Simpson
Journal:  East Afr Med J       Date:  1967-02

6.  Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice.

Authors:  Sándor Bereczky; Gunnel Lindegren; Helen Karlberg; Sara Akerström; Jonas Klingström; Ali Mirazimi
Journal:  J Gen Virol       Date:  2010-02-17       Impact factor: 3.891

7.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.

Authors:  Thomas W Geisbert; Lisa E Hensley; Peter B Jahrling; Tom Larsen; Joan B Geisbert; Jason Paragas; Howard A Young; Terry M Fredeking; William E Rote; George P Vlasuk
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

8.  Differential activation profiles of Crimean-Congo hemorrhagic fever virus- and Dugbe virus-infected antigen-presenting cells.

Authors:  Christophe N Peyrefitte; Magali Perret; Stephan Garcia; Raquel Rodrigues; Audrey Bagnaud; Sandra Lacote; Jean-Marc Crance; Guy Vernet; Daniel Garin; Michèle Bouloy; Gláucia Paranhos-Baccalà
Journal:  J Gen Virol       Date:  2009-10-07       Impact factor: 3.891

9.  Crimean-Congo hemorrhagic fever virus delays activation of the innate immune response.

Authors:  Ida Andersson; Helen Karlberg; Mehrdad Mousavi-Jazi; Luis Martínez-Sobrido; Friedemann Weber; Ali Mirazimi
Journal:  J Med Virol       Date:  2008-08       Impact factor: 2.327

Review 10.  Hemophagocytic syndromes and infection.

Authors:  D N Fisman
Journal:  Emerg Infect Dis       Date:  2000 Nov-Dec       Impact factor: 6.883

View more
  96 in total

1.  Assessment of rodents as animal models for Reston ebolavirus.

Authors:  Emmie de Wit; Vincent J Munster; Samia A Metwally; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

Review 2.  The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies.

Authors:  Marko Zivcec; Christina F Spiropoulou; Jessica R Spengler
Journal:  Antiviral Res       Date:  2020-01-22       Impact factor: 5.970

3.  Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus.

Authors:  S M Ghiasi; A H Salmanian; S Chinikar; S Zakeri
Journal:  Clin Vaccine Immunol       Date:  2011-10-19

4.  Evaluation of cytokines as Th1/Th2 markers in pathogenesis of children with Crimean-Congo hemorrhagic fever.

Authors:  Enver Sancakdar; Ahmet Sami Güven; Elif Bilge Uysal; Ali Kaya; Köksal Deveci; Hekim Karapınar; Ismail Akkar
Journal:  Int J Clin Exp Med       Date:  2014-03-15

Review 5.  Recent advances in research on Crimean-Congo hemorrhagic fever.

Authors:  Anna Papa; Ali Mirazimi; Iftihar Köksal; Augustin Estrada-Pena; Heinz Feldmann
Journal:  J Clin Virol       Date:  2014-10-22       Impact factor: 3.168

Review 6.  Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.

Authors:  Brian B Gowen; Brady T Hickerson
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 3.422

Review 7.  The role of ticks in the maintenance and transmission of Crimean-Congo hemorrhagic fever virus: A review of published field and laboratory studies.

Authors:  Aysen Gargili; Agustin Estrada-Peña; Jessica R Spengler; Alexander Lukashev; Patricia A Nuttall; Dennis A Bente
Journal:  Antiviral Res       Date:  2017-06-01       Impact factor: 5.970

8.  A virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virus.

Authors:  Stephanie Devignot; Eric Bergeron; Stuart Nichol; Ali Mirazimi; Friedemann Weber
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

9.  Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice.

Authors:  Michael E Lindquist; Xiankun Zeng; Louis A Altamura; Sharon P Daye; Korey L Delp; Candace Blancett; Kayla M Coffin; Jeffrey W Koehler; Susan Coyne; Charles J Shoemaker; Aura R Garrison; Joseph W Golden
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

10.  Heterologous protection against Crimean-Congo hemorrhagic fever in mice after a single dose of replicon particle vaccine.

Authors:  Jessica R Spengler; Stephen R Welch; Florine E M Scholte; JoAnn D Coleman-McCray; Jessica R Harmon; Stuart T Nichol; Éric Bergeron; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2019-08-01       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.